Barclays Reiterates "Underweight" Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Key Points

• Barclays has restated its underweight rating for Sarepta Therapeutics (NASDAQ:SRPT), reducing the price target from $18.00 to $10.00, indicating a potential downside of 39.55% from its current price.
• Wells Fargo downgraded its price objective for Sarepta from $65.00 to $48.00 while maintaining an "overweight" rating, highlighting mixed sentiments among analysts regarding the company's stock.
• Sarepta reported a loss of ($3.42) earnings per share for its latest quarter, significantly missing estimates, although revenue increased by 80.2% compared to the same quarter last year.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "underweight" rating reaffirmed by investment analysts at Barclays in a report issued on Sunday, MarketBeat reports.

Several other equities research analysts have also issued reports on the stock. Guggenheim lowered their price target on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Wells Fargo & Company lowered their price objective on shares of Sarepta Therapeutics from $65.00 to $48.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Baird R W lowered shares of Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, July 18th. JPMorgan Chase & Co. raised shares of Sarepta Therapeutics from an "underweight" rating to a "neutral" rating and set a $24.00 target price on the stock in a report on Tuesday. Finally, Morgan Stanley boosted their target price on shares of Sarepta Therapeutics from $15.00 to $20.00 and gave the stock an "equal weight" rating in a report on Tuesday. Six equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $49.12.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock traded down $0.48 on Friday, reaching $15.94. 3,742,666 shares of the stock were exchanged, compared to its average volume of 5,734,218. The firm has a fifty day moving average price of $24.24 and a two-hundred day moving average price of $61.50. The stock has a market cap of $1.57 billion, a PE ratio of -5.93 and a beta of 0.45. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00. Sarepta Therapeutics has a twelve month low of $10.41 and a twelve month high of $145.00.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The company had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. During the same period in the prior year, the company posted $0.73 EPS. The firm's quarterly revenue was up 80.2% on a year-over-year basis. Sell-side analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current year.

Institutional Trading of Sarepta Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of SRPT. Byrne Asset Management LLC purchased a new stake in Sarepta Therapeutics in the 1st quarter worth approximately $30,000. Center for Financial Planning Inc. bought a new position in shares of Sarepta Therapeutics in the 1st quarter worth $31,000. Ancora Advisors LLC increased its holdings in shares of Sarepta Therapeutics by 150.0% in the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock worth $32,000 after buying an additional 300 shares during the last quarter. Banque Transatlantique SA bought a new position in shares of Sarepta Therapeutics in the 1st quarter worth $44,000. Finally, Pandora Wealth Inc. bought a new position in shares of Sarepta Therapeutics in the 1st quarter worth $45,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.